Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

Phase 3

Completed

• Conditions: Multiple Myeloma; Auto Stem Cell Transplant
• Interventions: Drug: Bortezomib

• Registration Number: NCT01241708
• Lead Sponsor: Hackensack Meridian Health

Brief Summary

High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant recipients worldwide for the same or similar disorders.

Detailed Description

Many patients with multiple myeloma receive 2 stem cell transplantations within a few months of each other as part of their treatment. Usually the drug Melphalan is used for both transplants.

Bortezomib is a drug that is used for treating multiple myeloma and has been used in combination with melphalan for stem cell transplantation for patients with multiple myeloma.

The purpose of this trial is to study the effects of doing 2 transplants, first using melphalan and second using melphalan and bortezomib. The trial is aiming to find out if adding the Bortezomib to the second transplant will increase the chances of staying in remission longer.

Study Timeline

• Study Start: 2010-04-08
• Study First Submitted: 2010-11-15
• Study First Submitted QC: 2010-11-15
• Study First Posted: 2010-11-16
• Primary Completion: 2023-07-15
• Study Completion: 2023-07-15
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-21
• Last Update Posted: 2023-08-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 146

Inclusion Criteria

• Confirmed diagnosis of multiple myeloma with either Durie-Salmon stage I, II, or III or ISS stage I, II or III, less than 12 months since initiation of systemic therapy
• ≥8x106 CD34+cells/kg available in cryopreservation in aliquots appropriate for tandem transplants
• Age: 18-75 years at time of transplantation
• KPS 70-100%
• Recovery from complications of prior therapies
• Gender: There is no gender restriction

Exclusion Criteria

• Diagnosis other than multiple myeloma
• Chemotherapy or radiotherapy within 8 days of initiating treatment in this study
• Prior autologous or allogeneic transplantation (except as enrolled into this study)
• Uncontrolled bacterial, viral, fungal or parasitic infections

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Tandem Transplantation with Melphalan and Bortezomib	Bortezomib	Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma

Primary Outcome Measures

Name	Time	Method
To determine the progression-free survival of patients with multiple myeloma treated with tandem cycles of high-dose melphalan followed by high-dose melphalan in combination with bortezomib with autologous HSC transplantation.	3 years

Secondary Outcome Measures

Name	Time	Method
To determine the response rate, overall survival, and regimen-related toxicities of patients with multiple myeloma treated with high-dose melphalan or high-dose melphalan in combination with bortezomib given in tandem transplants.	lifetime

Trial Locations

Locations (1)

John Theurer Cancer Center @ Hackensack University Medical Center; 🇺🇸 Hackensack, New Jersey, United States